Cartesian Therapeutics Inc (RNAC)

04:47 AM

Barclays PLC Boosts Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

04:47 AM

Jan 18, 2025

Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Target Price at $42.86 - Defense World

Jan 18, 2025

Jan 17, 2025

Cartesian Therapeutics: Need To Wait For More Data For Its Novel mRNA Therapies - Seeking Alpha

Jan 17, 2025

Jan 15, 2025

Cartesian Therapeutics director Timothy Springer acquires $366k in stock By Investing.com - Investing.com Nigeria

Jan 15, 2025

Jan 15, 2025

Cartesian Therapeutics director Timothy Springer acquires $366k in stock - Investing.com India

Jan 15, 2025

Jan 15, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Consensus PT from Brokerages - MarketBeat

Jan 15, 2025

Jan 14, 2025

Cartesian Therapeutics’ (RNAC) Buy Rating Reaffirmed at Needham & Company LLC - Defense World

Jan 14, 2025

Jan 13, 2025

Needham & Company LLC Reiterates "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat

Jan 13, 2025

Jan 13, 2025

Cartesian Therapeutics Sets 2025 Strategy for Descartes-08 - TipRanks

Jan 13, 2025

Jan 13, 2025

Cartesian Therapeutics Highlights Progress and 2025 - GlobeNewswire

Jan 13, 2025

Jan 13, 2025

Cartesian's Descartes-08 Shows Strong Phase 2b Results in Myasthenia Gravis, Phase 3 Trial Planned - StockTitan

Jan 13, 2025

Jan 08, 2025

Myasthenia Gravis Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen R&D, Immunovant - The Globe and Mail

Jan 08, 2025

Jan 08, 2025

Myasthenia Gravis Market Poised for Significant Growth from - openPR

Jan 08, 2025

Jan 08, 2025

Cartesian Therapeutics chief scientific officer sells $42,782 in stock By Investing.com - Investing.com Australia

Jan 08, 2025

Jan 08, 2025

Geode Capital Management LLC Raises Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Jan 08, 2025

Jan 08, 2025

Cartesian therapeutics COO Emily English sells $30,149 in stock By Investing.com - Investing.com Nigeria

Jan 08, 2025

Jan 08, 2025

Cartesian Therapeutics CFO sells shares worth $134,035 By Investing.com - Investing.com South Africa

Jan 08, 2025

Jan 08, 2025

Carsten Brunn sells $289,764 in Cartesian Therapeutics shares By Investing.com - Investing.com South Africa

Jan 08, 2025

Jan 08, 2025

Cartesian Therapeutics CTO Metin Kurtoglu sells $81,790 in stock By Investing.com - Investing.com Canada

Jan 08, 2025

Jan 07, 2025

Cartesian Therapeutics CMO Milos Miljkovic sells $31,541 in stock By Investing.com - Investing.com Nigeria

Jan 07, 2025

Jan 07, 2025

Cartesian Therapeutics CFO sells shares worth $134,035 - Investing.com India

Jan 07, 2025

Jan 07, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Sells $40,412.24 in Stock - MarketBeat

Jan 07, 2025

Jan 07, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Metin Kurtoglu Sells 2,458 Shares - MarketBeat

Jan 07, 2025

Jan 07, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Insider Milos Miljkovic Sells 948 Shares - MarketBeat

Jan 07, 2025

Jan 07, 2025

Cartesian Therapeutics chief scientific officer sells $42,782 in stock - Investing.com

Jan 07, 2025

Jan 07, 2025

Cartesian Therapeutics CTO Metin Kurtoglu sells $81,790 in stock - Investing.com

Jan 07, 2025

Jan 07, 2025

Carsten Brunn sells $289,764 in Cartesian Therapeutics shares - Investing.com

Jan 07, 2025

Jan 07, 2025

Cartesian Therapeutics Announces New Employment Inducement Grants - The Manila Times

Jan 07, 2025

Jan 07, 2025

Cartesian Therapeutics Awards Stock Options to New Employees in Retention Move - StockTitan

Jan 07, 2025

Jan 07, 2025

Barclays PLC Purchases 7,849 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Jan 07, 2025

Jan 05, 2025

Risks Still Elevated At These Prices As Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Dive 33% - Simply Wall St

Jan 05, 2025

Jan 03, 2025

Critical Review: Cartesian Therapeutics (RNAC) vs. The Competition - Defense World

Jan 03, 2025

Jan 01, 2025

State Street Corp Has $2.54 Million Stock Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Jan 01, 2025

Dec 26, 2024

Cartesian Therapeutics (NASDAQ:RNAC) Trading 7.2% HigherStill a Buy? - MarketBeat

Dec 26, 2024

Dec 26, 2024

Cartesian Therapeutics ATM - Leerink Partners

Dec 26, 2024

Dec 24, 2024

Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.86 - Defense World

Dec 24, 2024

Dec 23, 2024

Cartesian therapeutics director Timothy Springer buys $965k in stock By Investing.com - Investing.com Nigeria

Dec 23, 2024

Dec 23, 2024

Cartesian therapeutics director Timothy Springer buys $965k in stock - Investing.com

Dec 23, 2024

Dec 21, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Dec 21, 2024

Dec 21, 2024

BNP Paribas Financial Markets Has $27,000 Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Dec 21, 2024

Dec 20, 2024

Cartesian Therapeutics initiated with a Buy at BTIG - Yahoo Finance

Dec 20, 2024

Dec 19, 2024

BTIG Research Initiates Coverage on Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat

Dec 19, 2024

Dec 19, 2024

BTIG initiates Buy rating on Cartesian Therapeutics stock highlighting mRNA CAR-T potential - Investing.com

Dec 19, 2024

Dec 18, 2024

Cartesian Therapeutics Awards Key Talent with mRNA Cell Therapy Stock Options in Strategic Growth Move - StockTitan

Dec 18, 2024

Dec 08, 2024

Fmr LLC Boosts Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Dec 08, 2024

Dec 08, 2024

Fmr LLC Has $45.97 Million Stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - MarketBeat

Dec 08, 2024